clinical analyzer News
-
Thermo Fisher Scientific Launches CE/IVD Marked Immunosuppressants Panel for the Cascadion SM Clinical Analyzer
Thermo Fisher Scientific, the world leader in serving science, announced today that it has expanded its European offering of pre-validated assays for the Thermo Scientific Cascadion SM Clinical Analyzer with the addition of the CE/IVD marked Cascadion SM Immunosuppressants (ISD) Panel. Clinical laboratories can now access a complete system developed to enable simultaneous testing of cyclosporine ...
-
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar ...
-
Thermo Fisher Scientific Announces Collaboration with Ortho Clinical Diagnostics
Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. Through this agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party ...
-
Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays
Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two clinical chemistry analyzers in the United States (U.S.) and Canada for drug screening in clinical and drug court laboratories. "Systematically and reliably testing for drugs of ...
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
-
Augmedics Announces FDA 510K Clearance and U.S. Launch of xvision, the First Augmented Reality Guidance System for Surgery
Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its groundbreaking xvision Spine system (XVS), the first AR guidance system to be used in surgery. xvision Spine allows surgeons to visualize the 3D spinal anatomy of a patient during surgery as if they had “x-ray vision,” and ...
By Augmedics
-
Unbiased gene fusion analysis required in future cancer diagnostics
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
By Qlucore AB
-
Microbiotica Wins Young Company of the Year at Business Weekly Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the Year” category is awarded to the most exciting recently incorporated enterprise in any sector that has made significant progress in the last 12 months. Microbiotica has been recognised for its continued development ...
-
Exploring next steps in cancer precision diagnostics using transcriptomics
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
By Qlucore AB
-
New data from pivotal studies with aflibercept 8 mg
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
By Bayer AG
-
EPA Funds New Center to Study Children’s Health
Washington, D.C. – EPA awarded Duke University nearly $8 million to support a 5-year study intended to improve public health. The new center at Duke University will be the first in the American South to study how social, environmental and genetic factors contribute to the recent rise in premature births and low birth weight. This grant is the largest in EPA’s history for a children’s ...
-
STALICLA will be leading computational drug repositioning in EU-funded project REPO4EU
STALICLA will play a key role in the consortium to build the Euro-Global Platform for Mechanism-based Drug Repurposing (REPO4EU), with an allocated budget of 1.7M to STALICLA Discovery and Data Science (DDS) unit. REPO4EU consortium aims to address the urgent need to develop new cost-effective therapies as well as to improve existing treatments through international cooperation, pooling ...
By STALICLA
-
Thermo Fisher Scientific Announces Collaborations to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization
Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating ...
-
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and ...
-
New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings
ImmunoCAP Specific IgE Stinging Insect Allergen Components have been cleared by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic use. Results from these component tests can act as a diagnostic aid to help specialists and other healthcare providers discriminate between true sensitization and cross reactivity, identify culprit insect(s) in patients with inconclusive patient ...
-
LightDeck Diagnostics and The Henry M. Jackson Foundation for the Advancement of Military Medicine receive $2M To Develop Rapid, Multiplexed Inflammation Test for Respiratory Illness
LightDeck Diagnostics, the company leveraging planar waveguide technology to deliver lab-quality diagnostics in minutes, today received a $2M contract from HJF, as funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Department of Defense (DoD). The funds will be used to develop a rapid, quantitative, multiplexed test for ...
-
Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions
“We have established an approach that transforms real-world, in-human treatment outcomes and safety data into extensive datasets to better characterize desirable and undesirable interactions between molecular pathways and drugs,” explains Dr. David Jackson, Chief Innovation Officer at Molecular Health and co-author on all three articles. “The studies demonstrate a standardized ...
-
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
-
Daxor Corporation CEO & President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on February 28, 2022 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: It is not every day you get to walk into Times Square in New York City and see your face and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you